Lavipharm S.A Total Liabilities
Lavipharm S.A total liabilities. Based on the latest financial reports, Lavipharm S.A (LAVI) has total liabilities worth €72.52 Million EUR (≈ $84.78 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Lavipharm S.A to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Lavipharm S.A (2014–2024)
Total liabilities of Lavipharm S.A from 2014 to 2024. This chart illustrates how Lavipharm S.A's total liabilities have evolved over time, based on quarterly financial data. Explore LAVI strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Lavipharm S.A Competitors by Total Liabilities
The table below lists competitors of Lavipharm S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nanjing Julong Science & Technology Co Ltd Class A
SHE:300644
|
China | CN¥1.68 Billion |
|
Lavvi Empreendimentos Imobiliários S.A
SA:LAVV3
|
Brazil | R$2.20 Billion |
|
Lionheart Holdings Unit
NASDAQ:CUBWU
|
USA | $10.07 Million |
|
F-SECURE OYJ
HE:FSECURE
|
Finland | €204.90 Million |
|
Kung Long Batteries Industrial Co Ltd
TW:1537
|
Taiwan | NT$2.01 Billion |
|
Beijing Jiaman Dress Co. Ltd. A
SHE:301276
|
China | CN¥448.73 Million |
|
Arbonia AG
SW:ARBN
|
Switzerland | CHF372.12 Million |
|
Valuetronics Holdings Limited
F:GJ7
|
Germany | €756.88 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Lavipharm S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LAVI total asset value.
Liquidity & Leverage Metrics
Lavipharm S.A Total Liabilities Ratios Explained
Lavipharm S.A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lavipharm S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lavipharm S.A (2014–2024)
The table below shows the annual total liabilities of Lavipharm S.A from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €72.52 Million ≈ $84.78 Million |
+0.70% |
| 2023-12-31 | €72.02 Million ≈ $84.19 Million |
-2.54% |
| 2022-12-31 | €73.89 Million ≈ $86.39 Million |
+17.89% |
| 2021-12-31 | €62.68 Million ≈ $73.28 Million |
-0.42% |
| 2020-12-31 | €62.94 Million ≈ $73.58 Million |
-1.38% |
| 2019-12-31 | €63.82 Million ≈ $74.62 Million |
+3.90% |
| 2018-12-31 | €61.43 Million ≈ $71.81 Million |
-5.10% |
| 2017-12-31 | €64.73 Million ≈ $75.67 Million |
-19.09% |
| 2016-12-31 | €80.00 Million ≈ $93.53 Million |
-45.50% |
| 2015-12-31 | €146.80 Million ≈ $171.62 Million |
+10.55% |
| 2014-12-31 | €132.79 Million ≈ $155.24 Million |
-- |
About Lavipharm S.A
Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sale, and wholesaling of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, respiratory system, gastrointestinal system, and urology; and over the counter (OTC) drugs,… Read more